ICM is a gene theraphy R&D company for osteoarthritis and age-related mascular disease. Stonebridge Ventures places high value to unique approach to osteoarthritis, its secured patent and outstanding R&D members of ICM, and proceeded with Series B investment in the firm.

Gene therapy of ICM is primary for degenerative diseases like osteoarthritis and mascular disease , so succeed of ICM’s approach liberated the aged from their age-related suffering.

ICM try to finish IND-profiling within 2018 ,and proceed clinical trial